血液学および血栓塞栓性疾患ジャーナル
オープンアクセス

概要

Brentuximab Vedotin and Diffuse Large B-cell Lymphoma

Shipra Gandhi, Neha Gupta

Brentuximab Vedotin., an anti-CD30 antibody drug conjugate (ADC) received FDA approval in 2011 for the treatment of relapsed/refractory Hodgkin's lymphoma and anaplastic large cell lymphoma based on 100% CD30 expression. In this review, we have discussed the various trials of Brentuximab Vedotin.in diffuse large B-cell lymphoma. Brentuximab Vedotin.is an ADC of monoclonal antibody conjugated with Monomethyl Auristatin E (MMAE), a microtubule inhibitor and hence facilitates selective delivery of potent MMAE to only the CD30 positive cells avoiding any off-target side effects. CD30 has restricted expression in normal tissues. According to the current trials, there does not seem to be an association between the efficacy of Brentuximab Vedotin and CD30 expression levels. Prospective trials are required to test the efficacy of Brentuximab Vedotin in diffuse large B-cell lymphoma and other malignancies and determine if CD30 positivity of tissue samples should be tested before administering Brentuximab Vedotin.